| Company Name: |
BOC Sciences |
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
ipsalazide manufacturers
- Ipsalazide
-
- $700.00
-
2026-05-11
- CAS:82101-17-5
- Purity: 99.43%
- Supply Ability: 10g
|
| | ipsalazide Basic information |
| Product Name: | ipsalazide | | Synonyms: | 5-[[4-[(Sodiooxycarbonylmethyl)carbamoyl]phenyl]azo]-2-hydroxybenzoic acid sodium salt;5-(Carboxymethylcarbamoyl-4-phenylazo)salicylic acid (disodium);Benzoic acid, 5-((4-(((carboxymethyl)amino)carbonyl)phenyl)azo)-2-hydroxy-, disodium salt | | CAS: | 82101-17-5 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | 82101-17-5.mol |  |
| | ipsalazide Chemical Properties |
| storage temp. | Store at -20°C | | solubility | Soluble in DMSO |
| | ipsalazide Usage And Synthesis |
| Uses | Ipsalazide is a novel sulfasalazine analog designed to release 5-aminosalicylic acid and a nontoxic carrier molecule in the gastrointestinal tract. | | in vivo | No deaths or visible abnormalities occurrs within 7 days of a single oral dose of ipsalazide (4 g/kg in mice or 2 g/kg in rats). No abnormalities were seen at postmortem. The ipsalazide carrier molecule (ABG) is readily absorbed, with nearly half of the dose appearing in the urine. However, around 40% of the ABG was not recovered, and it is possible that this has undergone further metabolism, with loss of the aromatic amine function which is the basis for the colorimetric measurement of ABG[1]. | | References | [1] Chan RP, et al. Studies of two novel sulfasalazine analogs, ipsalazide and balsalazide. Dig Dis Sci. 1983 Jul;28(7):609-15. DOI:10.1007/BF01299921 |
| | ipsalazide Preparation Products And Raw materials |
|